ECDC and the WHO Regional Office for Europe (WHO/Europe) recently concluded a crucial joint meeting focused on enhancing tuberculosis (TB) surveillance and monitoring across the WHO European Region.
Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
The European Respiratory Diseases Forecasting Hub (RespiCast) is open for weekly submission of several respiratory disease indicators such as influenza-like-illness, acute respiratory infection and COVID-19.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
ECDC and EMA have issued a joint statement on adapted COVID-19 vaccines and considerations for their use during the upcoming autumn 2023 vaccination campaigns.
To decrease the impact of COVID-19, and related hospitalisations and mortality, countries should plan for a continued roll-out of COVID vaccines in 2023.
Europe has agreed on measures to be applied in aviation in response to the specific localised worsening of the COVID-19 epidemiological situation in China, making recommendations which could potentially also be applied in other geographical regions in similar situations.